What the trial was testing
The STRENGTH enrolled 27 patients with spinal muscular atrophy. The study was sponsored by Novartis Pharmaceuticals and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
0 deaths and 0 study discontinuations from side effects in 27 patients.
Nature Medicine · 2026 · NCT05386680
These findings — that and no discontinuations from side effects with spinal onasemnogene in 27 SMA patients — were published in the Nature Medicine and represent the headline result of the study.
Researchers tracked outcomes across 27 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with spinal muscular atrophy, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
The intrathecal (spinal-fluid) form of onasemnogene abeparvovec is still in development and not yet FDA-approved as of early 2026. The IV form (Zolgensma) is FDA-approved for children under 2. Other approved SMA treatments include nusinersen (Spinraza) and risdiplam (Evrysdi). Ask a pediatric neurologist about approved options or open trials.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open spinal muscular atrophy trials
CuidAME: Longitudinal Data Collection From Patients With Spinal Muscular Atrophy in Spain
The goal of this observational study is to set up a longitudinal data collection study to perform a long-term follow-up of SMA patients in a real-world setting, and to standardise and homogenize the data collection process for SMA patient's data. Treated and untreated patients will be followed based on the routine clinical practice schedule.
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.